Mineralys reports FY2024 net loss $177.8M; cash $198.2M; pivotal data expected Q1-Q2 2025

Mineralys Therapeutics, Inc.

2024-FY EPS reported -$3.66

Net loss for FY2024 was $177.8M vs $71.9M in FY2023; R&D spend $168.6M vs $70.4M.
Cash, equivalents and investments $198.2M as of Dec 31, 2024; expected to fund operations through Q1 2026.
Topline data from pivotal Advance-HTN trial expected March 2025; Launch-HTN Phase 3 data in mid first half 2025.
Enrollment in Explore-CKD Phase 2 complete; topline data anticipated Q2 2025.
Initiating Phase 2 trial for lorundrostat in moderate-to-severe OSA and hypertension in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.